EARLY STAGE BREAST CANCER

This study tests a shorter, 5-day radiation treatment for early-stage breast cancer or DCIS after surgery. The goal is to see if this approach causes fewer side effects and is as effective as longer treatments at preventing cancer from coming back. About 90 women aged 50 and olde…

This study tests whether adding statins can prevent heart problems caused by HER2-targeted therapy in people with early-stage breast cancer. About 60 women will take statins alongside their cancer treatment to see if it reduces treatment delays or early stops. The goal is to keep…

This study tests whether adding an oral probiotic (Biolosion) to standard chemotherapy before surgery helps more women with early-stage triple-negative breast cancer achieve a complete response. About 192 participants will be randomly assigned to receive either standard therapy a…

This study tests a drug called trastuzumab deruxtecan, which delivers chemotherapy directly to cancer cells with low HER2 levels, given alone or with anastrozole (a hormone blocker). About 88 people with early-stage, hormone receptor positive breast cancer will receive treatment …

This study tests whether a different combination of targeted drugs works better for women with a certain type of breast cancer (HER2-positive, hormone receptor-positive) that still shows signs of cancer after initial treatment. About 300 women will receive either the standard two…

This study is for women with an early, hormone-sensitive type of breast cancer that has a higher chance of coming back. It tests whether a blood test (ctDNA) can identify who can safely skip chemotherapy and instead take a targeted pill (dalpiciclib) plus hormone therapy. About 3…

This study tests whether a 24-week exercise program (aerobic and strength training, 3 times a week) can help prevent breast cancer from returning in people with early-stage breast cancer. About 2,156 participants who have completed surgery and any chemotherapy or radiation will t…

This study tests whether a diagnostic test called HER2DX can help doctors choose the best treatment for people with early-stage HER2-positive breast cancer. About 304 participants will be split into two groups: one gets standard treatment without the test results, and the other g…

This study looks at how different amounts of aerobic exercise (like walking or cycling) affect heart and lung fitness in post-menopausal women who have finished treatment for early-stage breast cancer. About 152 women will take part. The goal is to find the best exercise plan to …

This study looks at how women with early-stage breast cancer rate their breast appearance and quality of life after a very short radiation treatment (5 days instead of the usual 3-6 weeks). 50 participants will be followed for up to 5 years. The goal is to see if this shorter rad…

This study looks at two ways to manage side effects from aromatase inhibitors, a hormone therapy for early-stage breast cancer. About half of women stop taking these pills early due to side effects, raising the risk of cancer returning. Researchers will compare switching to a dif…

This study looks at whether breast cancer patients can safely skip a medication called G-CSF during one part of their chemotherapy to reduce bone pain. About 242 people with early-stage breast cancer will either take G-CSF as usual or skip it while receiving paclitaxel. The main …

This study is testing whether adding new experimental drugs to standard chemotherapy before surgery can improve outcomes for people with breast cancer. It includes up to 5,000 participants with early-stage or locally advanced breast cancer. The goal is to use MRI scans and tissue…

This study is for people with high-risk early-stage breast cancer. It tests whether taking a low dose of the drug azacitidine before surgery can increase immune cells inside the tumor. The goal is to see if this approach can make the body's own defenses fight the cancer more effe…

This study looks at whether a simple blood test can find tiny bits of cancer DNA left in the body after breast cancer treatment. Finding this DNA, called minimal residual disease, may help predict if the cancer will come back. The study will follow 900 people with different types…